Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study

Main Article Content

Kyriakos P Papadopoulos
Taofeek K Owonikoko
Melissa L Johnson
Irene Brana
Marta Gil-Martin
Raymond P Perez
Victor Moreno
April K Salama
Emiliano Calvo
Nelson S Yee
Howard Safran
Antonio Gonzalez-Martin
Raid Aljumaily
Daruka Mahadevan
Kosalai K Mohan
Jingjin Li
Elizabeth Stankevich
Israel Lowy
Matthew G Fury
Jade Homsi

Keywords

cutaneous squamous cell carcinoma, non-melanoma skin cancer, safety, efficacy, PD-1

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Regeneron Pharmaceuticals Inc. and Sanofi.

 

Copyright 2018 SKIN